Anti-DLL4 & VEGF Reference Antibody (Navicixizumab)
Produktgrößen
100 ug
£495,00
CHBA058-100UG
1 mg
£1135,00
CHBA058-1MG
Über dieses Produkt
- SKU:
- CHBA058
- Zusätzliche Namen:
- Navicixizumab
- Anwendung:
- Cell-based/Functional Assay, Detection/Quantitation, ELISA, FACS, Flow Cytometry
- Buffer:
- 25mM histidine, 8% sucrose, 0.01% Tween80 pH6.2
- Klonalität:
- Recombinant Monoclonal
- Konzentration:
- 1 mg/ml
- Weitere Details:
- Anti-CD3 & BCMA Reference Antibody (Teclistamab) (CHB454) is expressed from CHO, with a configuration of DuoBody. The heavy chain type is IgG4-SPFALA, and the light chain type is lambda.It has a predicted MW of 143.64 kDa.
- Formulierung:
- 25mM histidine, 8% sucrose, 0.01% Tween80 pH6.2
- Immunogen:
- DLL4,VEGF
- Molekulargewicht:
- 146.17 kDa
- Reinheit:
- >95%
- Aufreinigung:
- Protein A Purified
- Versandbedingungen:
- Blue Ice
- Lagerbedingungen:
- -70[o]C Aliquot. Avoid freeze/thaw cycles., -20[o]C Aliquot. Avoid freeze/thaw cycles., 2-8[o]C Aliquot. Avoid freeze/thaw cycles.
- Hersteller:
- Sanyou Biopharmaceuticals
- Typ:
- Antibody: Recombinant Antibodies
- Datenblatt des Herstellers:CHBA058